Skip to main content

Table 5 UGT1A11 polymorphisms and their relationships with clinical characteristics (Continued Table 4)

From: Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer

Clinical features

Combination

TA6/6 −3156GG, 211GG

TA6/6, −3156GG, 211GA

TA6/7, −3156GA, 211GG

TA6/7, −3156GA, 211GA

TA6/6, −3156GG, 211AA

TA7/7, −3156AA, 211GG

Gender

 Male

39 (51.3)

21 (27.6)

8 (10.5)

2 (2.6)

4 (5.3)

2 (2.6)

 Female

8 (36.4)

9 (40.9)

5 (22.7)

0 (0.0)

0 (0.0)

0 (0.0)

χ 2, P

7.516, 0.185

Age

  < 57 years

19 (46.3)

13 (31.7)

7 (17.1)

1 (2.4)

1 (2.4)

0 (0.0)

  > 57 years

28 (49.1)

17 (29.8)

6 (10.5)

1 (1.8)

3 (5.3)

2 (3.5)

χ 2, P

3.541, 0.617

Family history

 Yes

1 (20.0)

2 (40.0)

1 (20.0)

0 (0.0)

1 (20.0)

0 (0.0)

 No

46 (49.5)

28 (30.1)

12 (12.9)

2 (2.2)

3 (3.2)

2 (2.2)

χ 2, P

3.571, 0.613

Alcohol history

 Yes

18 (56.3)

9 (28.1)

3 (9.4)

0 (0.0)

2 (6.3)

0 (0.0)

 No

29 (43.9)

21 (31.8)

10 (15.2)

2 (3.0)

2 (3.0)

2 (3.0)

χ 2, P

7.516, 0.185

Histological type

 Tubular adenocarcinoma

40 (53.3)

18 (24.0)

12 (16.0)

1 (1.3)

2 (2.7)

2 (2.7)

 Non-tubular adenocarcinoma

7 (30.4)

12 (52.2)

1 (4.3)

1 (4.3)

2 (8.7)

0 (0.0)

χ 2, P

11.488, 0.043

Differentiation

 Undifferentiated

5 (33.3)

6 (40.0)

1 (6.7)

1 (6.7)

2 (13.3)

0 (0.0)

 Low

32 (53.3)

18 (30.0)

8 (13.3)

0 (0.0)

1 (1.7)

1 (1.7)

 Moderate

10 (45.5)

6 (27.3)

3 (13.6)

1 (4.5)

1 (4.5)

1 (4.5)

 High

0 (0.0)

0 (0.0)

1 (100.0)

0 (0.0)

0 (0.0)

0 (0.0)

χ 2, P

14.419, 0.494

Growth patterns

 Expansive

1 (50.0)

1 (50.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

 Invasive

34 (47.9)

19 (26.8)

11 (15.5)

2 (2.8)

3 (4.2)

2 (2.8)

 Expansive + invasive

12 (48.0)

10 (40.0)

2 (8.0)

0 (0.0)

1 (4.0)

0 (0.0)

χ 2, P

5.361, 0.866

Metastasis

 Yes

23 (44.2)

19 (36.5)

5 (9.6)

1 (1.9)

3 (5.8)

1 (1.9)

 No

24 (52.2)

11 (23.9)

8 (17.4)

1 (2.2)

1 (2.2)

1 (2.2)

χ 2, P

3.558, 0.615

Depth of invasion

 T1

8 (57.1)

3 (21.4)

1 (7.1)

0 (0.0)

0 (0.0)

2 (14.3)

 T2

1 (20.0)

1 (20.0)

3 (60.0)

0 (0.0)

0 (0.0)

0 (0.0)

 T3

2 (66.7)

0 (0.0)

1 (33.3)

0 (0.0)

0 (0.0)

0 (0.0)

 T4

36 (47.4)

26 (34.2)

8 (10.5)

2 (2.6)

4 (5.3)

0 (0.0)

χ 2, P

21.061, 0.135

Lymph node metastasis

 N0

25 (48.1)

15 (28.8)

9 (17.3)

1 (1.9)

1 (1.9)

1 (1.9)

 N1

16 (50.0)

8 (25.0)

4 (12.5)

1 (3.1)

2 (6.3)

1 (3.1)

 N2

3 (27.3)

7 (63.6)

0 (0.0)

0 (0.0)

1 (9.1)

0 (0.0)

 Undetermined

3 (100.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

χ 2, P

15.280, 0.431

Distant metastasis

 M0

42 (48.8)

23 (26.7)

13 (15.1)

2 (2.3)

4 (4.7)

2 (2.3)

 M1

5 (41.7)

7 (58.3)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

χ 2, P

8.417, 0.135

TNM staging

 I

9 (50.0)

4 (22.2)

3 (16.7)

0 (0.0)

0 (0.0)

2 (11.1)

 IIA-IIC

16 (55.2)

6 (20.7)

6 (20.7)

0 (0.0)

1 (3.4)

0 (0.0)

 IIIA-IIIC

17 (43.6)

13 (33.3)

4 (10.3)

2 (5.1)

3 (7.7)

0 (0.0)

 IVA-IVB

5 (41.7)

7 (58.3)

0 (0.0)

0 (2.6)

0 (5.3)

0 (0.0)

χ 2, P

23.131, 0.081

  1. The values in bold indicate the statistically significant difference